Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO).

Depatux-M EGFR antibody drug conjugate glioblastoma targeted therapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
03 Jun 2021
Historique:
received: 08 05 2021
revised: 28 05 2021
accepted: 01 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

Depatuxizumab Mafodotin (Depatux-M; ABT-414) is an antibody-drug conjugate consisting of a specific antibody against activated EGFR and a cytotoxic agent with antimicrotubule activity. The INTELLANCE 2/EORTC 1410 phase 2 trial produced interesting results for the combination regimen of Depatux-M and temozolomide in EGFR-amplified glioblastoma patients at first recurrence. For the first time worldwide, our work investigated the clinical outcome and safety of this combination in a real-life population. Patients were enrolled from seven AINO (Italian Association of Neuro-Oncology) Institutions. The major inclusion criteria were: histologically confirmed diagnosis of glioblastoma, EGFR-amplified, one or more prior systemic therapies and ECOG PS ≤ 2. According to the original schedule, patients received Depatux-M 1.25 mg/kg every 2 weeks combined with temozolomide. The primary endpoints of the study were overall survival and safety. A total of 36 patients were enrolled. The median age was 57 years, ECOG PS was 0-1 in 28 patients (88%), MGMT methylated status was found in 22 (64%), 15 patients (42%) received the combined treatment as second-line therapy. The median OS was 8.04 months (95% CI, 5.3-10.7), the 12 month-OS was 37%. On univariate and multivariate analyses, the MGMT methylation status was the only factor resulting significantly associated with survival. Grade 3 ocular toxicity occurred in 11% of patients; no grade 4 ocular toxicity was reported. No death was considered to be drug-related. The study reported the first "real world" experience of Depatux-M plus temozolomide in recurrent glioblastoma patients. Encouraging clinical benefits were demonstrated, even though most patients were treated beyond second-line therapy. Overall, the results are close to those reported in the previous phase 2 trial. Toxicity was moderate and manageable.

Sections du résumé

BACKGROUND BACKGROUND
Depatuxizumab Mafodotin (Depatux-M; ABT-414) is an antibody-drug conjugate consisting of a specific antibody against activated EGFR and a cytotoxic agent with antimicrotubule activity. The INTELLANCE 2/EORTC 1410 phase 2 trial produced interesting results for the combination regimen of Depatux-M and temozolomide in EGFR-amplified glioblastoma patients at first recurrence. For the first time worldwide, our work investigated the clinical outcome and safety of this combination in a real-life population.
MATERIALS AND METHODS METHODS
Patients were enrolled from seven AINO (Italian Association of Neuro-Oncology) Institutions. The major inclusion criteria were: histologically confirmed diagnosis of glioblastoma, EGFR-amplified, one or more prior systemic therapies and ECOG PS ≤ 2. According to the original schedule, patients received Depatux-M 1.25 mg/kg every 2 weeks combined with temozolomide. The primary endpoints of the study were overall survival and safety.
RESULTS RESULTS
A total of 36 patients were enrolled. The median age was 57 years, ECOG PS was 0-1 in 28 patients (88%), MGMT methylated status was found in 22 (64%), 15 patients (42%) received the combined treatment as second-line therapy. The median OS was 8.04 months (95% CI, 5.3-10.7), the 12 month-OS was 37%. On univariate and multivariate analyses, the MGMT methylation status was the only factor resulting significantly associated with survival. Grade 3 ocular toxicity occurred in 11% of patients; no grade 4 ocular toxicity was reported. No death was considered to be drug-related.
CONCLUSIONS CONCLUSIONS
The study reported the first "real world" experience of Depatux-M plus temozolomide in recurrent glioblastoma patients. Encouraging clinical benefits were demonstrated, even though most patients were treated beyond second-line therapy. Overall, the results are close to those reported in the previous phase 2 trial. Toxicity was moderate and manageable.

Identifiants

pubmed: 34204877
pii: cancers13112773
doi: 10.3390/cancers13112773
pmc: PMC8199759
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Neuro Oncol. 2020 May 15;22(5):684-693
pubmed: 31747009
Oncologist. 2019 Apr;24(4):521-528
pubmed: 30266892
Ther Adv Med Oncol. 2020 May 27;12:1758835920907543
pubmed: 32550861
Cancers (Basel). 2020 Aug 14;12(8):
pubmed: 32823925
Neuro Oncol. 2010 Jan;12(1):95-103
pubmed: 20150372
Neuro Oncol. 2015 Mar;17(3):430-9
pubmed: 25140039
Front Oncol. 2020 Oct 14;10:593461
pubmed: 33154952
JAMA Oncol. 2020 Jul 1;6(7):1003-1010
pubmed: 32437507
Lancet Oncol. 2019 Jan;20(1):110-119
pubmed: 30522967
Neuro Oncol. 2019 Oct 9;21(10):1263-1272
pubmed: 31125418
Cancers (Basel). 2020 Dec 26;13(1):
pubmed: 33375286
J Clin Oncol. 2018 Dec 10;36(35):3477-3484
pubmed: 30351999
J Clin Oncol. 2020 Jan 1;38(1):81-99
pubmed: 31743054
Neuro Oncol. 2019 Jan 1;21(1):106-114
pubmed: 29982805
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
N Engl J Med. 2017 Nov 16;377(20):1954-1963
pubmed: 29141164
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Neurooncol Adv. 2019 Dec 09;2(1):vdz051
pubmed: 32642719
Cancers (Basel). 2020 Dec 15;12(12):
pubmed: 33333830
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1206-11
pubmed: 23182702
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Mol Cancer Ther. 2016 Apr;15(4):661-9
pubmed: 26846818

Auteurs

Marta Padovan (M)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

Marica Eoli (M)

Unit of Molecular Neuro-Oncology, Besta-IRCCS, 20133 Milan, Italy.

Alessia Pellerino (A)

Department of Neuro-Oncology, University and City of Health and Science Hospital, 10126 Turin, Italy.

Simona Rizzato (S)

Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, Italy.

Claudia Caserta (C)

Medical Oncology Unit, Azienda Ospedaliera S. Maria, 05100 Terni, Italy.

Matteo Simonelli (M)

Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Italy.
IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.

Maria Michiara (M)

Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.

Mario Caccese (M)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

Elena Anghileri (E)

Unit of Molecular Neuro-Oncology, Besta-IRCCS, 20133 Milan, Italy.

Giulia Cerretti (G)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

Roberta Rudà (R)

Department of Neuro-Oncology, University and City of Health and Science Hospital, 10126 Turin, Italy.
Department of Neurology, San Giacomo Hospital, 31033 Castelfranco Veneto, Italy.

Vittorina Zagonel (V)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

Giuseppe Lombardi (G)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

Classifications MeSH